San Francisco-based McKesson has agreed to settle claims with the Department of Justice, Drug Enforcement Administration and various U.S. Attorney's offices alleging suspicious order reporting practices for controlled substances by paying $150 million and suspending at least three distribution center registrations for two years, according to Reuters.
McKesson has suspended the DEA registrations for specific products at its Aurora, Colo., Livonia, Mich., Washington Courthouse, Ohio, and Lakeland, Fla., distribution warehouses for between one and three years, according to McKesson's 8-K filing with the SEC.
The company's Landover, Md., distribution center is also being investigated, according to Reuters.
More articles on health IT:
Senators form working group to address EHR usability
10 most-read health IT stories in April
Teladoc to file for IPO: 5 things to know